Abstract

PROCESS DEVELOPMENT OF SIMPLE BY HPLC METHOD FOR ESTIMATION OF EPALRESTAT IN SOLID DOSAGE FORM AND HUMAN PLASMA

Vijay Pratap Singh*, Dr. Mohit Chaturvedi, Shabnam Khan, Jeevan Patel, Ramakant Sharma, Saharsh Mishra and Dr. Rakesh Patel

ABSTRACT

Epalrestat is indicated for prevention, and treatment of diabetes to improve with the peripheral nerve disorders (flu numbness, pain), feeling abnormal vibration and cardiac abnormalities. Epalrestat is a carboxylic acid derivative that inhibits aldose reductase, a rate-limiting enzyme of the polvol pathway. In hyperglycemia, epalrestat is an uncompetitive aldose reductase inhibitor, significantly reduces intracellular sorbitol accumulation, which has been related in the pathogenesis of late-onset diabetic complications like neuropathy, retinopathy, and nephropathy.

Keywords: Carboxylic acid derivatives that inhibits aldose reeducates in diabetic neuropathy, retinopathy, and nephropathy.